FDA Brief

Warning letters Drugs

FDA warning letter to

Hadassah Healing Oils Ltd

High riskIssued Jun 17Posted Jun 23Center for Drug Evaluation and Research (CDER)

FDA warns South Africa's Hadassah Healing Oils that its Prostate Blend oil is an unapproved new drug sold online with disease claims.

What happened

FDA reviewed the company's website, hadassahhealingoils.com, in May 2026 rather than conducting an inspection. The review found the product "Prostate Blend" promoted with claims that it assists with prostate healing and prostate cancer healing and helps relieve the urge to urinate. FDA says the product is a new drug with no approved application, so selling it in the United States is illegal.

What FDA found

  1. Website statements that the product treats prostate disease and prostate cancer make it a drug under the law.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  2. The product is not generally recognized as safe and effective for its labeled uses, which makes it a "new drug."

    Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  3. There is no FDA-approved application for the product, so shipping it across state lines is against the law.

    Sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)

What FDA wants

FDA tells the company to investigate the root causes, take corrective and preventive steps, and send a written response with supporting documents within 15 business days, citing reference number 729191. The company may also submit information showing why the product is not in violation.

Who should pay attention

  • online sellers of herbal and oil products that make health claims
  • consumers buying prostate remedies from websites
  • regulatory staff tracking CDER unapproved-drug warning letters

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk